Top

Journal of Neurology

Published in:

01-09-2012 | Letter to the Editors

Inflammatory demyelinating CNS disorder in a case of X-linked Charcot–Marie–Tooth disease: positive response to natalizumab

Authors: Jochen H. Weishaupt, Claudia Ganser, Mathias Bähr

Published in: Journal of Neurology | Issue 9/2012

Excerpt

Dear Sirs, …

Zhou L, Griffin JW (2003) Demyelinating neuropathies. Curr Opin Neurol 16(3):307–313PubMedCrossRef

Bergoffen J et al (1993) Connexin mutations in X-linked Charcot–Marie–Tooth disease. Science 262(5142):2039–2042PubMedCrossRef

Kleopa KA, Scherer SS (2006) Molecular genetics of X-linked Charcot–Marie–Tooth disease. Neuromolecular Med 8(1–2):107–122PubMed

Scherer SS et al (1995) Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci 15(12):8281–8294PubMed

Bahr M et al (1999) Central visual, acoustic, and motor pathway involvement in a Charcot–Marie–Tooth family with an Asn205Ser mutation in the connexin 32 gene. J Neurol Neurosurg Psychiatry 66(2):202–206PubMedCrossRef

Nicholson GA, Yeung L, Corbett A (1998) Efficient neurophysiologic selection of X-linked Charcot–Marie–Tooth families: ten novel mutations. Neurology 51(5):1412–1416PubMedCrossRef

Taylor RA et al (2003) The CNS phenotype of X-linked Charcot–Marie–Tooth disease: more than a peripheral problem. Neurology 61(11):1475–1478PubMedCrossRef

Panas M et al (2004) Charcot–Marie–Tooth disease type 1A with central nervous system involvement in two generations. J Neurol 251(4):484–485PubMedCrossRef

Hanemann CO et al (2003) Transient, recurrent, white matter lesions in X-linked Charcot–Marie–Tooth disease with novel connexin 32 mutation. Arch Neurol 60(4):605–609PubMedCrossRef

10.

Sargiannidou I et al (2009) Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects. J Neurosci 29(15):4736–4749PubMedCrossRef

11.

Paulson HL et al (2002) Transient central nervous system white matter abnormality in X-linked Charcot–Marie–Tooth disease. Ann Neurol 52(4):429–434PubMedCrossRef

12.

Isoardo G et al (2005) X-linked Charcot–Marie–Tooth disease and progressive-relapsing central demyelinating disease. Neurology 65(10):1672–1673PubMedCrossRef

13.

Parman Y et al (2007) X-linked Charcot–Marie–Tooth disease and multiple sclerosis. J Neurol 254(7):953–955PubMedCrossRef

14.

Ginsberg L et al (2004) Coexistent hereditary and inflammatory neuropathy. Brain 127(Pt 1):193–202PubMedCrossRef

15.

Dyck PJ et al (1982) Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 57(4):239–246PubMed

16.

Bird SJ, Sladky JT (1991) Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology 41(3):437–439PubMedCrossRef

17.

Oppenheimer DR (1978) The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 4(2):151–162PubMedCrossRef

Title: Inflammatory demyelinating CNS disorder in a case of X-linked Charcot–Marie–Tooth disease: positive response to natalizumab
Authors: Jochen H. Weishaupt
Claudia Ganser
Mathias Bähr
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 9/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6467-9

2024 ASCO Annual Meeting

Springer Medicine

Inflammatory demyelinating CNS disorder in a case of X-linked Charcot–Marie–Tooth disease: positive response to natalizumab

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2012

Lobar cerebral microbleeds associated with transient focal neurological symptoms followed by symptomatic intracerebral hemorrhage

Multiple subcortical acute ischemic lesions reflect small vessel disease rather than cardiogenic embolism

Clinical impact and predictors of carotid artery in-stent restenosis

Patterns of white matter diffusivity abnormalities in Leber’s hereditary optic neuropathy: a tract-based spatial statistics study

Susceptibility to pattern glare following stroke

Substance abuse may be a risk factor for earlier onset of Huntington disease